Form 4 for AURA Aura Biosciences, Inc.
Accepted 2025-06-18 00:00:00 ET · period of report 2025-06-17 · accession 0000950170-25-087890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-06-18 | 2025-06-17 | AURA | Johnson David Michael | Dir | A - Grant | $0.00 | +13.0K | 179.2K | +8% | $0 |
| D | 2025-06-18 | 2025-06-17 | AURA | Johnson David Michael | Dir | A - Grant | $0.00 | +17.0K | 17.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-17 | A | A | 13,000 | $0.00 | 179,167 | D | — | — | (F1) These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-06-17 | A | A | 17,000 | $0.00 | 17,000 | D | $6.18 · — to 2035-06-17 | 17,000 Common Stock | (F5) This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |